Could a new injection beat insulin for diabetes control?
NCT ID NCT06871761
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tested a new drug called HR17031 against the standard insulin glargine in 393 adults with type 2 diabetes whose blood sugar was not well controlled despite using basal insulin and metformin. The study measured changes in HbA1c (average blood sugar), weight, and safety over 26 weeks. The goal was to see if HR17031 could provide better blood sugar control with fewer side effects like weight gain.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HR17031 injection (a new drug) compared to insulin glargine (standard insulin)
- What this could lead to
- If it works, HR17031 could offer better blood sugar control with less weight gain than standard insulin for people with type 2 diabetes.
- What could go wrong
- This is a Phase 3 trial, but results are not yet published. The new drug may not prove superior or could have unexpected side effects like hypoglycemia.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT PATIENTS WITH TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Zhu Xianyi Memorial Hospital, Tianjin Medical University
Tianjin, Tianjin Municipality, 300400, China